Trials / Completed
CompletedNCT01300468
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
A Phase I Study of Oral PHA-848125AC Given Daily For 7 Consecutive Days Every 2 Weeks or for 4 Consecutive Days A Week for 3 Consecutive Weeks Every 4 Weeks to Adult Patients With Advanced/Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid tumor patients. Objectives of the study were to determine the maximum tolerated dose and the dose that can be recommended for Phase II investigations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PHA-848125AC |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2009-05-01
- Completion
- 2009-12-01
- First posted
- 2011-02-21
- Last updated
- 2011-02-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01300468. Inclusion in this directory is not an endorsement.